Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.59 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.59 |
| ▸ | F13A1 | P00488 | 3/20 | 0.55 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.53 |
| ▸ | PTGFR | P43088 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.50 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.50 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.50 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.50 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.50 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.50 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.50 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.50 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.50 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.50 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.50 |
| ▸ | LTB4R | Q15722 | 4/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30427741 | 1.00 | MAPT (0.59) | MAPTRXFP1F13A1PTGER1PTGFR | |
| SCHEMBL2487912 | 1.00 | MAPT (0.59) | MAPTRXFP1F13A1PTGER1PTGFR | |
| SCHEMBL29462363 | 0.93 | HDAC3 (0.57) | MAPTRXFP1PTGER1PTGFRMEN1 | |
| SCHEMBL1265758 | 0.93 | HDAC3 (0.57) | MAPTRXFP1PTGER1PTGFRMEN1 | |
| SCHEMBL29444401 | 0.85 | MEN1 (0.59) | PTGER1MEN1ALDH1A1KMT2ATAAR1 | |
| SCHEMBL246473 | 0.85 | MEN1 (0.59) | PTGER1MEN1ALDH1A1KMT2ATAAR1 | |
| SCHEMBL22826566 | 0.85 | MAPT (0.67) | MAPTRXFP1F13A1HDAC3HDAC4 | |
| SCHEMBL30428005 | 0.84 | FFAR4 (0.49) | MAPTRXFP1F13A1MEN1ALDH1A1 | |
| SCHEMBL22826567 | 0.81 | MAPT (0.62) | MAPTRXFP1F13A1PTGER1HDAC3 | |
| SCHEMBL15637935 | 0.80 | MPO (0.53) | PTGER1PTGFRMEN1ALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100041717-A1 | N-((3-BENZYL)-2,2-(BIS-PHENYL)-PROPAN-1-AMINE DERIVATIVES AS CETP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROSIS AND CARDIOVASCULAR DISEASES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-02-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100041717-A1 | N-((3-BENZYL)-2,2-(BIS-PHENYL)-PROPAN-1-AMINE DERIVATIVES AS CETP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROSIS AND CARDIOVASCULAR DISEASES | CETP, APOB, CES1 | MAPT 2812/4885RXFP1 1594/4885F13A1 2628/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.